Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | DUT | P33316 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17185826 | 1.00 | CA12 (0.42) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL2721499 | 1.00 | CA12 (0.42) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL25390430 | 1.00 | CA12 (0.42) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL23611465 | 1.00 | CA12 (0.42) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL20564496 | 0.96 | CA12 (0.44) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL20294716 | 0.93 | CA12 (0.40) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL4739003 | 0.93 | CA12 (0.40) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL19543562 | 0.89 | CA12 (0.36) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL29704301 | 0.89 | ALDH1A1 (0.38) | CA12CA1CA9DUTALDH1A1 | |
| SCHEMBL5854114 | 0.87 | CA12 (0.40) | CA12CA1CA9DUTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4463451-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2024-11-20 | — | — | EP | disclosed |
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023134712-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| WO-2022238737-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | WO | disclosed |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4058065-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2022-09-21 | — | — | EP | disclosed |
| US-20220280650-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-08-25 | — | — | US | disclosed |
| US-11291732-B1 | Compounds for degrading α-synuclein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (HK) | 2022-04-05 | — | — | US | disclosed |
| WO-2021097243-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280650-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | SNCA, PARK7, PRNP | CA12 4010/4885CA1 3596/4885CA9 4039/4885 |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | CA12 4146/4885CA1 4770/4885CA9 3418/4885 |
| US-12377152-B2 | Compounds for degrading alpha-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | CA12 4010/4885CA1 3596/4885CA9 4039/4885 |
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | CA12 4092/4885CA1 2988/4885CA9 4181/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | CA12 4092/4885CA1 2988/4885CA9 4181/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | CA12 4092/4885CA1 2988/4885CA9 4181/4885 |
| US-11291732-B1 | Compounds for degrading α-synuclein aggregates and uses thereof | SNCA, PARK7, PRNP | CA12 4255/4885CA1 3939/4885CA9 4239/4885 |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | CA12 4155/4885CA1 2992/4885CA9 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.